We guarantee to make you
the best humanized antibody

We have been humanizing antibodies since 1987 and our expertise has been used by the world's leading pharmaceutical and biotech companies.

The technique we use (CDR grafting) was developed at the MRC giving our scientists unrivalled knowledge about this specialised discipline. We are the only company offering an antibody engineering service who have humanized drugs on the market.

Our BioTherapeutics team explain our antibody engineering services.

NOT
HEARD
OF US? YOU'LL
KNOW
OUR
WORK!

No antibody – no invoice!

Unlike our competitors we continue applying our proven experience until we reach the optimum humanized candidate. What’s more, we believe in payment by results; we will deliver the best candidate and you don’t have to risk wasting time
or money.

Adding value

We offer other engineering services such as affinity maturation and biophysical characterisation.

Unrivalled expertise

  • We have humanized more than 50 antibodies.

  • Our development work has already delivered two marketed drugs Tysabri® and Actemra®.

  • A further six are in clinical trials (including Vedolizumab).

  • Another two are in preclinical studies.

Our process: 12-15 weeks

  • One week to generate several optimised human antibody designs.

  • 12-15 weeks to design the variants, build the constructs and screen for the optimum candidate antibody.

  • We keep you up to date on progress at all times.

Sequencing

The mouse heavy and light chain variable antibody genes are extracted from the client’s hybridoma cell line using our proprietary amplification primers in a polymerase chain reaction (PCR) and then sequenced.

In-silico modelling

Humanization design, using selection of human antibody gene fragment regions from MRC Technology's extensive proprietary database, is carried out. Rodent CDRs are then grafted into human frameworks.

Synthesis

We synthesise as many humanized antibody variants as determined by the design process, with no limit. We make all the variants identified in the design.

Chimerisation

We also make a chimeric antibody, which involves combining the mouse antibody variable genes with human antibody constant genes. This acts as a positive control for the humanization.

Candidate selection

The heavy and light chain candidates are combined in all possible variations and screened against the chimeric antibody for retention of antigen binding affinity, specificity and expression. The best candidates are selected as finished products.



Please note: All commercial projects are subject to a short due diligence process before acceptance.

Collaborative early stage drug discovery

The pharmaceutical industry is pulling out of riskier, early stage research, and it is harder for scientists with novel findings to realise therapeutic potential. Our Centre for Therapeutics Discovery provides scientists with a central resource for industry quality drug discovery, development and commercialisation How you could benefit by collaborating on a project with us: • Raise new antibodies or humanize existing antibodies for therapeutic use • Screen against large compound collection & develop with medicinal chemistry expertise • Income generated from programs shared with your organisations

Researchers

Submit your small molecule or antibody target details through our Call for Targets website.

TTOs

We can help you to commercialise your portfolio of targets. We work in partnership with you and will organise roadshows and 1-1 support for your scientists.

Antibody engineering - a guide to our Antibody Engineering approach and service


DOWNLOAD NOW

Please send us an email using the form below or call

Your first name Last Name company email address re-enter email address phone no inc country code
 

John Kelly on +44(0)20 8906 2826

Your message

Please complete thereCAPTCHA code then hit this button to send your email